Current Stage of Interleukin 2 Receptor Targeted Therapy1)

Abstract
The overview summarizes a new and selective form of immunosuppressive therapy by using anti-Interleukin-2 receptor monoclonal antibodies, which may soon become an important form of recipient treatment in organ/tissue transplantation or/and of patient treatment with autoimmune diseases.

This publication has 0 references indexed in Scilit: